Trial Profile
Responder rates of two low dose combinations of Angeliq (0.5 mg E2/0.5 mg DRSP and 0.5 mg E2/0.25 mg DRSP) in postmenopausal women with moderate to severe vasomotor symptoms.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jul 2011
Price :
$35
*
At a glance
- Drugs Estradiol (Primary) ; Estradiol/drospirenone (Primary)
- Indications Menopausal syndrome
- Focus Therapeutic Use
- Sponsors Bayer HealthCare
- 04 Jul 2011 New trial record